<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04653961</url>
  </required_header>
  <id_info>
    <org_study_id>RMC096020ctil</org_study_id>
    <nct_id>NCT04653961</nct_id>
  </id_info>
  <brief_title>Evaluation of a Decision Support System for People With Diabetes Who Use Multiple Daily Insulin Injections- Feasibility Study</brief_title>
  <official_title>Evaluation of a Decision Support System for People With Diabetes Who Use Multiple Daily Insulin Injections- Feasibility Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rabin Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Leona M. and Harry B. Helmsley Charitable Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>DreaMed Diabetes</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Rabin Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      An open label, prospective study that will include up to 24 subjects with Type 1 Diabetes&#xD;
      treated with Multiple Daily Injections ( MDI) and Self Monitoring of Blood Glucose (SMBG) or&#xD;
      intermittent Continuous Glucose Monitoring (CGM).&#xD;
&#xD;
      The study will include screening, a 2-4-week run-in period and a 8 weeks intervention period.&#xD;
      Subjects will be asked to record their insulin delivery during basal/bolus insulin treatment&#xD;
      (using dedicated apps ) and their daily activities (meals, physical activity etc.) using&#xD;
      electronic log (implemented on Dedicated Apps), for a total period of 12-14 weeks.&#xD;
&#xD;
      The goal of this study is to evaluate the safety of a decision support system for adjustment&#xD;
      of insulin treatment plan for people with diabetes using multiple daily injections and&#xD;
      monitoring glucose by SMBG or intermittent CGM&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 2021</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sensor glucose percentage of time in hypoglycemia below 54 mg/dl</measure>
    <time_frame>11 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Sensor glucose percentage of time in hyperglycemia above 250 mg/dl</measure>
    <time_frame>11 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of readings within range of 70-180 mg/dl</measure>
    <time_frame>11 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HbA1C post study treatment</measure>
    <time_frame>11 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Serious Adverse Events</measure>
    <time_frame>11 weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Percentage of readings above 180 mg/dl</measure>
    <time_frame>11 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of readings below 70 mg/dl</measure>
    <time_frame>11 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Mean sensor glucose</measure>
    <time_frame>11 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Glucose variability</measure>
    <time_frame>11 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number of recommendations for changes in the treatment plan per patient</measure>
    <time_frame>11 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number of recommendations for changes in the treatment plan per iteration</measure>
    <time_frame>11 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number of physician overrides of the study system recommendations</measure>
    <time_frame>11 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Total insulin dose</measure>
    <time_frame>11 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>The amount of basal insulin dose</measure>
    <time_frame>11 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>The amount of bolus insulin dose</measure>
    <time_frame>11 weeks</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Type1diabetes</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject's glucose and insulin data will be transferred to the DreaMed Advisor Pro system. Optimization of insulin treatment plan will be done using the DreaMed Advisor Pro Decision Support System-MDI algorithm. After approval by the study physician (may override the suggestions for safety reasons), the treatment plan will be sent to the subject to be followed for the following 2.5 weeks. The study team will follow-up with a phone call to the subject to verify the subject received the updated treatment plan.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>DreaMed Advisor Pro DSS-MDI algorithm</intervention_name>
    <description>The DreaMed Advisor Pro software is a proprietary algorithm, designed to provide a comprehensive analysis of individual diabetes data which consists of glucose levels and insulin delivery history. the Advisor Pro algorithm identifies glucose patterns and their possible causes, which may hamper the patient's glucose control, and recommend on adjustment to the patient-specific insulin treatment profiles as well as suggestions for personalized diabetes management tips (such as timing of meal boluses, bolus delivery compliance and personalized glucose targets).</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Documented Type 1 Diabetes for at least 1 year prior to study enrolment&#xD;
&#xD;
          -  Aged ≥ 14 to 40 years&#xD;
&#xD;
          -  HbA1c of 7 ≤ A1c ≤ 10%&#xD;
&#xD;
          -  Using basal-bolus MDI therapy:&#xD;
&#xD;
               1. Basal insulin: Glargine, Degludec, or detemir and up to sum of 72 units of basal&#xD;
                  insulin&#xD;
&#xD;
               2. Bolus insulin: regular insulin, rapid analogues or ultra-rapid analogues&#xD;
&#xD;
          -  Subjects willing to follow study instructions:&#xD;
&#xD;
               1. For SMBG users (FGM with a reader): measure capillary blood glucose at least 4&#xD;
                  times a day . Document blood glucose level, insulin delivery, meals and daily&#xD;
                  activities. Wear CGM.&#xD;
&#xD;
               2. For CGM users: Use CGM according to manufacture instructions, document insulin&#xD;
                  delivery, meals and daily activities.&#xD;
&#xD;
          -  Subjects using CGM or SMBG that are compatible with data transmission to the study&#xD;
             diabetes management system (i.e. for CGM, FGM with a reader).&#xD;
&#xD;
          -  Subjects have home computer connected to the internet.&#xD;
&#xD;
          -  Subjects have a smart phone compatible with study requirements.&#xD;
&#xD;
          -  Subjects willing and able to sign a written informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  An episode of diabetic keto-acidosis within the month prior to study entry and/or&#xD;
             severe hypoglycemia resulting in seizure or loss of consciousness in the month prior&#xD;
             to enrolment.&#xD;
&#xD;
          -  Concomitant diseases/ treatment that influence metabolic control or any significant&#xD;
             diseases /conditions including psychiatric disorders and substance abuse that in the&#xD;
             opinion of the investigator is likely to affect the subject's ability to complete the&#xD;
             study or compromise patients' safety&#xD;
&#xD;
          -  Relevant severe organ disorders (diabetic nephropathy, diabetic retinopathy, diabetic&#xD;
             foot syndrome) or any secondary disease or complication of diabetes mellitus, such as:&#xD;
&#xD;
               -  Subject has unstable or rapidly progressive renal disease or is receiving&#xD;
                  dialysis&#xD;
&#xD;
               -  Subject has active proliferative retinopathy&#xD;
&#xD;
               -  Active gastroparesis 4. Participation in any other interventional study 5. Female&#xD;
                  subject who is pregnant or planning to become pregnant within the planned study&#xD;
                  duration&#xD;
&#xD;
          -  Subject is in the &quot;honeymoon&quot; phase - i.e. less than 0.5 insulin units/kg per day.&#xD;
&#xD;
          -  Drug or alcohol abuse.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Moshe Phillip, MD</last_name>
    <role>Study Director</role>
    <affiliation>Rabin Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Revital Nimri, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rabin Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Moshe Phillip, MD</last_name>
    <phone>972-544-795995</phone>
    <email>moshe.phillip@phillipmd.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alona Hamou, MSc</last_name>
    <phone>972-3-9253282</phone>
    <email>alonah@clalit.org.il</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>schneider children medical center of Israel</name>
      <address>
        <city>Petach Tikva</city>
        <zip>49202</zip>
        <country>Israel</country>
      </address>
    </facility>
    <contact>
      <last_name>Moshe Phillip, Prof</last_name>
      <phone>972-3-9253282</phone>
      <email>mosheph@clalit.org.il</email>
    </contact>
    <investigator>
      <last_name>Revital Nimri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>November 28, 2020</study_first_submitted>
  <study_first_submitted_qc>November 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 4, 2020</study_first_posted>
  <last_update_submitted>February 1, 2021</last_update_submitted>
  <last_update_submitted_qc>February 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

